Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Non-Current Assets (2021 - 2025)

Indivior Pharmaceuticals (INDV) has 3 years of Non-Current Assets data on record, last reported at $489.0 million in Q4 2024.

  • For Q4 2024, Non-Current Assets fell 2.4% year-over-year to $489.0 million; the TTM value through Dec 2021 reached $388.0 million, changed N/A, while the annual FY2024 figure was $489.0 million, 2.4% down from the prior year.
  • Non-Current Assets reached $489.0 million in Q4 2024 per INDV's latest filing, down from $501.0 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $501.0 million in Q4 2023 and bottomed at $388.0 million in Q4 2021.
  • Average Non-Current Assets over 3 years is $459.3 million, with a median of $489.0 million recorded in 2024.
  • The widest YoY moves for Non-Current Assets: up 2.4% in 2024, down 2.4% in 2024.
  • A 3-year view of Non-Current Assets shows it stood at $388.0 million in 2021, then rose by 29.12% to $501.0 million in 2023, then fell by 2.4% to $489.0 million in 2024.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $489.0 million in Q4 2024, $501.0 million in Q4 2023, and $388.0 million in Q4 2021.